Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.81 |
| ▸ | MC4R | P32245 | 1/20 | 0.65 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.65 |
| ▸ | DRD4 | P21917 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.63 |
| ▸ | ACHE | P22303 | 1/20 | 0.61 |
| ▸ | CHKA | P35790 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | CCR3 | P51677 | 1/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2228267 | 1.00 | SIGMAR1 (0.81) | SIGMAR1MC4RHRH3DRD4LMNA | |
| SCHEMBL1045330 | 1.00 | SIGMAR1 (0.81) | SIGMAR1MC4RHRH3DRD4LMNA | |
| SCHEMBL1043563 | 0.98 | SIGMAR1 (0.86) | SIGMAR1MC4RHRH3DRD4LMNA | |
| Water SCHEMBL17460165 | 0.98 | SIGMAR1 (0.77) | SIGMAR1MC4RHRH3DRD4LMNA | |
| SCHEMBL1044952 | 0.98 | SIGMAR1 (0.86) | SIGMAR1MC4RHRH3DRD4LMNA | |
| SCHEMBL577331 | 0.98 | SIGMAR1 (0.86) | SIGMAR1MC4RHRH3DRD4LMNA | |
| SCHEMBL576379 | 0.98 | SIGMAR1 (0.86) | SIGMAR1MC4RHRH3DRD4LMNA | |
| SCHEMBL1777747 | 0.95 | SIGMAR1 (0.81) | SIGMAR1MC4RHRH3DRD4LMNA | |
| SCHEMBL13952 | 0.95 | SIGMAR1 (0.81) | SIGMAR1MC4RHRH3DRD4LMNA | |
| Ammonia Solution, Strong SCHEMBL3699405 | 0.93 | SIGMAR1 (0.77) | SIGMAR1MC4RHRH3DRD4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119119105-A | Multifunctional silanol compound and preparation method and application thereof | 杭州师范大学 | 2024-12-13 | — | — | CN | claimed |
| EP-2336315-B1 | Enzymatic encoding methods for efficient synthesis of large libraries | NUEVOLUTION AS (DK) | 2017-07-19 | — | — | EP | claimed |
| US-20150038534-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. | 2015-02-05 | — | — | US | claimed |
| CN-103221047-B | Compounds and methods | TEMPERO PHARMACEUTICALS INC | 2014-12-17 | — | — | CN | claimed |
| US-8901156-B2 | Compounds and methods | TEMPERO PHARMACEUTICALS, INC. (US) | 2014-12-02 | — | — | US | claimed |
| CN-103221047-A | Compounds and methods | TEMPERO PHARMACEUTICALS INC | 2013-07-24 | — | — | CN | claimed |
| WO-2011088181-A9 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-01-31 | — | — | WO | claimed |
| WO-2013009830-A1 | METHODS OF TREATMENT | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-01-17 | — | — | WO | claimed |
| WO-2013009810-A1 | METHODS OF TREATMENT | TEMPERO PHARMACEUTICALS, INC. (US) | 2013-01-17 | — | — | WO | claimed |
| EP-2533783-A1 | COMPOUNDS AND METHODS | Tempero Pharmaceuticals, Inc. (US) | 2012-12-19 | — | — | EP | claimed |
| WO-2011088181-A1 | COMPOUNDS AND METHODS | TEMPERO PHARMACEUTICALS, INC. (US) | 2011-07-21 | — | — | WO | claimed |
| EP-2336315-A2 | Enzymatic encoding methods for efficient synthesis of large libraries | Nuevolution A/S (DK) | 2011-06-22 | — | — | EP | claimed |
| EP-2318363-A1 | HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS | Nuevolution A/S (DK) | 2011-05-11 | — | — | EP | claimed |
| WO-2009152824-A1 | HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS | NUEVOLUTION A/S (DK) | 2009-12-23 | — | — | WO | claimed |
| CN-122079977-A | Carbazole compound and organic electroluminescent device thereof | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122010948-A | Aromatic amine compound and organic electroluminescent device thereof | 长春海谱润斯科技股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| CN-122011003-A | Chiral silatetrahydro-1-naphthylamine compound and synthesis method thereof | 扬州大学 | 2026-05-12 | — | — | CN | disclosed |
| US-4808213-A | 2,3,6-substituted phenylimidazole derivatives and the use thereof as growth regulators | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-02-28 | — | — | US | disclosed |
| EP-0279543-A1 | Process for the preparation of an azetidine and intermediates therefor | A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) (US) | 1988-08-24 | — | — | EP | disclosed |
| EP-0125714-B1 | PREPARATION OF 1-SUBSTITUTED AZETIDIN-3-OL AND ACID HALID THEREOF | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1987-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038534-A1 | COMPOUNDS AND METHODS | XDH, LPXN, CCNY | SIGMAR1 804/4885MC4R 2342/4885HRH3 776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.